Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | EBP | Q15125 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745932 | 0.78 | SIGMAR1 (0.44) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL4000984 | 0.78 | SIGMAR1 (0.44) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL2562460 | 0.77 | KDM1A (0.43) | SIGMAR1EBPPDK1 | |
| SCHEMBL2561103 | 0.77 | HRH3 (0.37) | KDM4EALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL296970 | 0.76 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL296048 | 0.76 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL4024634 | 0.76 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL296969 | 0.76 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1TDP1 | |
| SCHEMBL15331505 | 0.74 | KDM1A (0.36) | PDK1 | |
| SCHEMBL29614975 | 0.74 | SIGMAR1 (0.59) | SIGMAR1EBPKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3283550-B1 | CATALYST CONTAINING AMIDINE GROUPS | SIKA TECH AG (CH) | 2020-12-16 | — | — | EP | disclosed |
| EP-3294803-B1 | GUANIDINE GROUP CONTAINING CATALYST | SIKA TECH AG (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-10414875-B2 | Catalyst containing guanidine groups | SIKA TECHNOLOGY AG (CH) | 2019-09-17 | — | — | US | disclosed |
| US-10392480-B2 | Catalyst containing amidine groups | SIKA TECHNOLOGY AG (CH) | 2019-08-27 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180171082-A1 | CATALYST CONTAINING AMIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-05-31 | — | — | US | disclosed |
| EP-3294803-A1 | CATALYST CONTAINING GUANIDINE GROUPS | Sika Technology AG (CH) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180840-A1 | CATALYST CONTAINING GUANIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414875-B2 | Catalyst containing guanidine groups | GMPS, GMNN, RNMT | SIGMAR1 764/4885EBP 3715/4885KDM4E 998/4885 |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | GMPS, RNMT, GMNN | SIGMAR1 1068/4885EBP 3674/4885KDM4E 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.